Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohns disease
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and…
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET…
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohns and Colitis Organization 20th Annual Congress
January 23, 2025 16:05 ET | Source: Abivax Abivax Announces Presentation of…